Description: Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.
Home Page: www.legendbiotech.com
2101 Cottontail Lane
Somerset,
NJ
08873
United States
Phone:
732 317 5050
Officers
| Name | Title |
|---|---|
| Dr. Ying Huang Ph.D. | CEO & Director |
| Ms. Lori A. Macomber CPA | Chief Financial Officer |
| Mr. Doug Wallace | Vice President of Global Operations |
| Dr. Guowei Fang Ph.D. | Chief Scientific Officer & Head of Business Development |
| Ms. Joanne Choi | Senior Manager of Investor Relations |
| Mr. James Pepin J.D. | General Counsel |
| Mr. Tim Roberts | Global Compliance Officer |
| Deborah Wong | Executive Director of Strategic Marketing & Corporate Communications |
| Ms. Elaine Qian | VP & Global Head of Human Resources |
| Dr. Yuhong Qiu Ph.D. | Senior Vice President of Global Regulatory Affairs |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 1000 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.7855 |
| Price-to-Sales TTM: | 13.9764 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2400 |